Pharmaceutical Research

, Volume 31, Issue 9, pp 2266–2275 | Cite as

Directed Self-assembled Nanoparticles of Probucol Improve Oral Delivery: Fabrication, Performance and Correlation

  • Zhiwen Zhang
  • Shijun Jiang
  • Zeying Liu
  • Baohua Niu
  • Wangwen Gu
  • Yaping Li
  • Jingbin Cui
Research Paper



We are reporting on the development of a unique drug delivery platform by directed self-assembly technique to improve the oral delivery of hydrophobic drugs.


Herein, a series of probucol directed self-assembled nanoparticles (PDN) were developed with two components of probucol and surfactant such as Tween 20, Tween 80, D-alpha-tocopheryl polyethylene glycol 1,000 succinate (TPGS) and HS-15, which was respectively named as T20-PDN, T80-PDN, TP-PDN and HS-PDN. The formation of various PDNs was determined by in vitro characterization and the physicochemical properties of these PDNs were determined. Moreover, the performance of PDN in enhancing the oral delivery and possible correlation between the in vitro properties and in vivo performances were investigated.


PDN was homogenous nanometer-sized particles with negative surface charge. The cellular uptake of probucol in Caco-2 cell monolayer was respectively increased 1.15, 1.82, 1.59 and 5.31-fold by these PDN. In particular, the oral bioavailability of these PDN was significantly improved 3.0, 4.1, 5.4 and 10.4 folds compared with the free drug suspension. The enhanced cellular uptake and oral bioavailability were correlated with the characters of involved surfactants and the particle size of PDN.


Thereby, the directed self-assembled nanoparticles could provide a new strategy for enhancing the oral delivery of hydrophobic drugs.


correlation directed self-assembly nanoparticles oral delivery probucol 



Zhiwen Zhang and Shijun Jiang contributed equally to this work.

The National Basic Research Program of China (2013CB932503 and 2013CB932704), the National Natural Science Foundation of China (81270047, 81373359) and SA-SIBS Scholarship Program are gratefully acknowledged for financial support.


  1. 1.
    Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–48.PubMedCrossRefGoogle Scholar
  2. 2.
    Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557–70.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Zhang Z, Gao F, Jiang S, Ma L, Li Y. Nano-based drug delivery system enhances the oral absorption of lipophilic drugs with extensive presystemic metabolism. Curr Drug Metab. 2012;13(8):1110–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Mu H, Holm R, Mullertz A. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int J Pharm. 2013;453(1):215–24.PubMedCrossRefGoogle Scholar
  5. 5.
    Cooper ER. Nanoparticles: a personal experience for formulating poorly water soluble drugs. J Control Release. 2010;141(3):300–2.PubMedCrossRefGoogle Scholar
  6. 6.
    Zhang Z, Huang Y, Gao F, Gao Z, Bu H, Gu W, et al. A self-assembled nanodelivery system enhances the oral bioavailability of daidzein: in vitro characteristics and in vivo performance. Nanomedicine (London). 2011;6(8):1365–79.CrossRefGoogle Scholar
  7. 7.
    Zhang ZW, Bu HH, Gao ZW, Huang Y, Gao F, Li YP. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm. 2010;394(1–2):147–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Grzelczak M, Vermant J, Furst EM, Liz-Marzan LM. Directed self-assembly of nanoparticles. ACS Nano. 2010;4(7):3591–605.PubMedCrossRefGoogle Scholar
  9. 9.
    Zhao Y, Thorkelsson K, Mastroianni AJ, Schilling T, Luther JM, Rancatore BJ, et al. Small-molecule-directed nanoparticle assembly towards stimuli-responsive nanocomposites. Nat Mater. 2009;8(12):979–85.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang P, Cheetham AG, Lin YA, Cui H. Self-assembled tat nanofibers as effective drug carrier and transporter. ACS Nano. 2013;7(7):5965–77.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Sanchez-Iglesias A, Grzelczak M, Altantzis T, Goris B, Perez-Juste J, Bals S, et al. Hydrophobic interactions modulate self-assembly of nanoparticles. ACS Nano. 2012;6(12):11059–65.PubMedGoogle Scholar
  12. 12.
    Wang W, Chau Y. Efficient and facile formation of two-component nanoparticles via aromatic moiety directed self-assembly. Chem Commun. 2011;47(37):10224–6.CrossRefGoogle Scholar
  13. 13.
    Date AA, Desai N, Dixit R, Nagarsenker M. Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances. Nanomedicine (London). 2010;5(10):1595–616.CrossRefGoogle Scholar
  14. 14.
    Xia DN, Cui FD, Piao HZ, Cun DM, Piao HY, Jiang YB, et al. Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. Pharm Res. 2010;27(9):1965–76.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang ZW, Huang J, Jiang SJ, Liu ZY, Gu WW, Yu HJ, et al. Porous starch based self-assembled nano-delivery system improves the oral absorption of lipophilic drug. Int J Pharm. 2013;444(1–2):162–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Thakuria R, Delori A, Jones W, Lipert MP, Roy L, Rodriguez-Hornedo N. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm. 2013;453(1):101–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Yamashita S, Matsuzawa Y. Where are we with probucol: a new life for an old drug? Atherosclerosis. 2009;207(1):16–23.PubMedCrossRefGoogle Scholar
  18. 18.
    Heeg JF, Hiser MF, Satonin DK, Rose JQ. Pharmacokinetics of probucol in male-rats. J Pharm Sci. 1984;73(12):1758–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: performance and mechanism. J Control Release. 2011;149(2):168–74.PubMedCrossRefGoogle Scholar
  20. 20.
    Rizza L, Frasca G, Nicholls M, Puglia C, Cardile V. Caco-2 cell line as a model to evaluate mucoprotective proprieties. Int J Pharm. 2012;422(1–2):318–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang Z, Gao F, Jiang S, Chen L, Liu Z, Yu H, et al. Bile salts enhance the intestinal absorption of lipophilic drug loaded lipid nanocarriers: mechanism and effect in rats. Int J Pharm. 2013;452(1–2):374–81.PubMedCrossRefGoogle Scholar
  22. 22.
    Xin H, Chen L, Gu J, Ren X, Wei Z, Luo J, et al. Enhanced anti-glioblastoma efficacy by PTX-loaded PEGylated poly(varepsilon-caprolactone) nanoparticles: in vitro and in vivo evaluation. Int J Pharm. 2010;402(1–2):238–47.PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang L, Yao J, Zhou JP, Wang T, Zhang Q. Glycyrrhetinic acid-graft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs. Int J Pharm. 2013;441(1–2):654–64.PubMedCrossRefGoogle Scholar
  24. 24.
    Nassar T, Rom A, Nyska A, Benita S. A novel nanocapsule delivery system to overcome intestinal degradation and drug transport limited absorption of P-glycoprotein substrate drugs. Pharm Res. 2008;25(9):2019–29.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhang Z, Ma L, Jiang S, Liu Z, Huang J, Chen L, et al. A self-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor. J Control Release. 2013;166(1):30–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Roger E, Lagarce F, Garcion E, Benoit JP. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (London). 2010;5(2):287–306.CrossRefGoogle Scholar
  27. 27.
    Larsen AT, Akesson P, Jureus A, Saaby L, Abu-Rmaileh R, Abrahamsson B, et al. Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis. Pharm Res. 2013. doi: 10.1007/s11095-013-1145-x.Google Scholar
  28. 28.
    Memvanga PB, Eloy P, Gaigneaux EM, Preat V. In vitro lipolysis and intestinal transport of beta-arteether-loaded lipid-based drug delivery systems. Pharm Res. 2013;30(10):2694–705.PubMedCrossRefGoogle Scholar
  29. 29.
    Pongpeerapat A, Wanawongthai C, Tozuka Y, Moribe K, Yamamoto K. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int J Pharm. 2008;352(1–2):309–16.PubMedCrossRefGoogle Scholar
  30. 30.
    Pongpeerapat A, Higashi K, Tozuka Y, Moribe K, Yamamoto K. Molecular interaction among probucol/PVP/SDS multicomponent system investigated by solid-state NMR. Pharm Res. 2006;23(11):2566–74.PubMedCrossRefGoogle Scholar
  31. 31.
    Fukami T, Ishii T, Io T, Suzuki N, Suzuki T, Yamamoto K, et al. Nanoparticle processing in the solid state dramatically increases the cell membrane permeation of a cholesterol-lowering drug, probucol. Mol Pharm. 2009;6(3):1029–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Zhang Z, Gao F, Bu H, Xiao J, Li Y. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats. Nanomedicine: NBM. 2012;8(5):740–7.CrossRefGoogle Scholar
  33. 33.
    Kulkarni SA, Feng SS. Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res. 2013;30(10):2512–22.PubMedCrossRefGoogle Scholar
  34. 34.
    Yanez JA, Wang SW, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2011;63(10–11):923–42.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Zhiwen Zhang
    • 1
  • Shijun Jiang
    • 2
  • Zeying Liu
    • 2
  • Baohua Niu
    • 1
  • Wangwen Gu
    • 1
  • Yaping Li
    • 1
  • Jingbin Cui
    • 2
  1. 1.Center of Pharmaceutics, Shanghai Institute of Materia MedicaChinese Academy of SciencesShanghaiChina
  2. 2.School of PharmacyEast China University of Science and TechnologyShanghaiChina

Personalised recommendations